Virtu Financial’s Altamira Therapeutics Ltd CYTO Stock Holding History

Virtu Financial’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-312	Closed	-$36K	–	2356
2022 Q3	$36K	Buy	312 +280	+875%	+$46.5K	﹤0.01%	1277
2022 Q2	$6K	Buy	+32	New	+$10.3K	﹤0.01%	1456
2021 Q1	–	Sell	-160	Closed	-$167K	–	2183
2020 Q4	$167K	Buy	+160	New	+$103K	0.02%	918
2019 Q3	–	Sell	-49	Closed	-$54K	–	1949
2019 Q2	$54K	Buy	49 +41	+513%	+$71.2K	﹤0.01%	1221
2019 Q1	$21K	Buy	8 +6	+300%	+$19.3K	﹤0.01%	1283
2018 Q4	$8K	Sell	2 -12	-86%	-$61.3K	﹤0.01%	1461
2018 Q3	$40K	Buy	+14	New	+$36.9K	﹤0.01%	1330
2018 Q2	–	Sell	-3	Closed	-$35K	–	2629
2018 Q1	$35K	Hold	3	–	–	﹤0.01%	1764
2017 Q4	$129K	Buy	+3	New	+$163K	0.01%	1837

Other funds holding CYTO

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SCA

Stonebridge Capital Advisors St Paul, Minnesota $1.43B AUM 21.98% 1-Year Est. Return

Virtu Financial's CYTO Position: Q4 2022 in Review

Virtu Financial sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2022, closing a stake of 312 shares — an estimated $36K sold.

Virtu Financial first reported a position in CYTO in Q4 2017 and held it in 9 quarters. The position peaked at $167K in Q4 2020. 6 funds tracked by Wall St. Rank hold CYTO as of Q4 2022.

Virtu Financial reported no remaining Altamira Therapeutics Ltd position as of Q4 2022 after selling out during the quarter.
Virtu Financial sold 312 Altamira Therapeutics Ltd shares in Q4 2022, an estimated $36K.
Virtu Financial first reported a position in Altamira Therapeutics Ltd in Q4 2017 and held it in 9 quarters.
Virtu Financial's Altamira Therapeutics Ltd position peaked at $167K in Q4 2020.
6 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2022.

Based on Virtu Financial's 13F filing for Q4 2022, filed 15 Feb 2023.